ClinicalTrials.gg
CompletedNCT01416324Updated Jun 20, 2017

First Time in Human Study Using GSK2330672

A Phase 1 interventional study of placebo and 0.1 mg GSK2330672 in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · GlaxoSmithKline.

Enrollment
108th of 125
17 · median 70
Started
2011
with 8 others
Phase 1
51 of 136
none open now
Registered
107th of 136
by date

Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 108th largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2011, is one of 51 in phase 1, and was the 107th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.

Read the detailed description

This is a single blind, randomized, placebo-controlled, dose escalating, crossover, first time in human study to examine safety, tolerability, pharmacokinetic and pharmacodynamic parameters of GSK233672. Single blind indicates that the subjects and investigator are blinded to treatment but the GSK study team could be unblinded for ongoing review of interim safety data required for dose escalation.

Subjects will participate in 4 dosing periods. Subjects will enter the clinic prior to dinner time on the evening of Day -1 of each period and will remain in residence through the morning of Day 3. Barring any safety or tolerability concerns, subjects will be released at this time provided they have had at least 1 bowel movement after dosing in the clinic.

Subjects will return for their next scheduled dosing period. This process will be repeated for each dosing period. Subjects will return approximately 1 week after check out from their last dosing period for a follow up visit. Subjects will receive standardized meals meeting specific criteria starting with dinner on Day-1 and continuing through Day 1. Standard meals will be provided for the remainder of their stay in the clinic. After an overnight fast, subjects will take their study drug on the morning of Day 1. Dosing will be followed by breakfast and frequent blood sampling to assess pharmacokinetic and pharmacodynamic parameters. Scheduled assessments of heart rate, blood pressure, respiratory rate, ECGs, and clinical laboratories will be obtained to monitor subject safety. Subjects will be connected to cardiac telemetry monitors and will periodically undergo spirometry testing of ventilation parameters. Stool form and frequency of bowel movements will be recorded. All fecal samples will be collected from participants for 48 hours after dosing of study drug, or until they have had at least 1 bowel movement after dosing, whichever occurs first.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • pharmacodynamics
  • first time in human
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy volunteer
  • 18-60 yrs of age
  • for subjects age 50 and above: negative fecal occult blood test within 3 months prior to expected start of dosing, and normal results from sigmoidoscopy or colonoscopy within 5 yrs prior to dosing.
  • if female, must be of non-

Exclusion criteria

Exclusion Criteria:

  • pregnant or breastfeeding females
  • positive
  • positive Hep B, or Hep C within 3 months of screening
  • positive drugs of abuse screening
  • triglycerides > 250 mg/dL
  • current or chronic history of liver disease
  • any gastrointestinal or gastrointestinal related conditions that could affect fat or bile acid reabsorption
  • pancreatitis
  • colon cancer or 1st degree relative who has had colon cancer
  • abnormal lung function tests
  • inability to perform lung function tests
  • unwilling to abstain from smoking, alcohol, caffeine, illicit drugs as directed by the site staff
  • exposure to more than 4 new chemical entities in the 12 months prior to the first dosing day.
  • where participation in the study would results in donation of more than approximately 550mL of blood in a 56-day period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    GSK2330672

    experimental study drug

    Drug: 0.1 mg GSK2330672 · Drug: 0.3 mg GSK2330672 · Drug: 1 mg GSK2330672 · Drug: 3 mg GSK2330672 · Drug: 10 mg GSK2330672 · Drug: 30 mg GSK2330672 · Drug: 60 mg GSK2330672

  • Placebo comparator
    Placebo

    placebo

    Drug: placebo

Interventions

  • Drugplacebo

    Vehicle used to dilute the powder for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

  • GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

06

What researchers measure

Primary outcomes

  1. Change in vital signs

    frequency and absolute value change in heart rate, blood pressure, respiration rate relative to placebo

    Time frame: 1, 2, 4, 8, 12, 24, 48 hours

  2. ECGs relative to placebo

    frequency of clinically significant changes in 12-lead ECG parameters relative to placebo

    Time frame: 1, 2, 4, 8, 12, 24, 48 hours

  3. Changes in clinical lab results

    Changes in clinical chemistry, hematology, urinalysis results relative to placebo

    Time frame: 24 hours

  4. lung function tests

    Measure changes in FEV, FVC, FEF 25-75%, PEFR relative to placebo

    Time frame: 1, 3, 8, 24 hours

  5. Adverse events relative to placebo

    Frequency and severity of adverse events relative to placebo

    Time frame: 48 hour monitoring

Secondary outcomes

  1. Measurement of the maximum concentration (Cmax) for study drug

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours

  2. Measurement of the time to achieve maximum concentration (tmax) for study drug

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours

  3. Measurement of area under the curve (AUC) for study drug

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours

  4. Measurement of half life (t 1/2) of study drug

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours

  5. Measurement of apparent clearance (CL/F) of the study drug

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours

  6. Measurement of the apparent volume of distribution (V/F) of the study drug

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours

07

Study locations

1 site
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Sep 2011, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Aug 15, 2011
StartActual
Jun 15, 2011
Primary completionActual
Sep 9, 2011
CompletionActual
Sep 9, 2011
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01416324
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 15, 2011
Start date
Jun 15, 2011
Primary completion
Sep 9, 2011
Completion
Sep 9, 2011
Last update
Jun 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linerixibat

Start the discussion